Many of the genes encoding growthfactors, growthfactor receptors, enzymes, and other effector molecules that regulate normal cell growth are designated protooncogenes. Oncogenes, those genes associated with cellular transformation, differ from their protooncogenic progenitors by being mutated, overexpressed, or expressed at inappropriate times or locations in the cell. One of the activities of growth factors is to prime cells to undergo programmed cell death, which is characterized by a series of morphologicchanges called apoptosis. In normal cells, specific mediators must be activated or suppressed to bypass programmed cell death. In tumor cells, either the pathways leading to apoptosis are not functional or the mediators that normally "rescue" cells from this fate are overexpressed or constitutively activated. In addition to the biochemical pathways that drive cell division, there are others that limit cell proliferation; these, designated tumor suppressors, anti-oncogenes, or recessive oncogenes, must be inactivated in normal cells to allow passage through the cell cycle and cell proliferation. In contrast to oncogenes, which are overexpressed or activated 
Aberrant production or action of growth factors or of the biochemical cascades they initiate acts as a dominant process, requiring changes in only a single allele to lead to oncogenesis.
Several genes that regulate programmed cell death had been previously proposed to be oncogenes, which suggests that these genes will be dominant mediators.
In contrast, mutations in both copies of a suppressor gene are required to ablate their function; they thus act as recessive oncogenes.
As the processes regulating growth of normal and malignant cells are identified, they become targets for therapy. Indeed, several potential antitumor agents that primarily attack the biochemical pathways induced by growth factors are currently in clinical trials. Similarly, because growth factors and the biochemical pathways they initiate either in their normal protooncogemc or mutated oncogemc forms play a role in tumor initiation and progression, their presence or absence in tumors may correlate with prognosis. Indeed, concentrations of neu and myc, the protein products of protooncogenes neu and myc in ovarian and breast cancer, appear to provide significant prognostic indicators. Thus, the ability to measure the presence and action of these factors could potentially be used as components of screening protocols or to determine which patients may or may not respond to specific therapies.
This article is not planned as an overview of the current literature, but rather utilizes specific oncogenes, tumor-suppressor genes, and anti-apoptosis genes to emphasize particular points. As such, the reader is directed to many of the recent excellent review articles referenced throughout this manuscript for a more detailed description of each gene described. (Table 1) The growth and differentiation of eukaryotic cells are subject to tight regulation by both positive-and negative-signaling pathways. All normal quiescent cells can be induced to grow by the action of growth factors (1) (2) (3) (4) . These growth factors bind to specific transmembrane receptors, which transduce signals across the cell membrane to the cytoplasm. Hormone receptors (thyroid hormone receptor/v-erbA)
Classes of Oncogenes

Anti-apoptosis genes bcI2
Tumor-suppressor genes RB p53
we will categorize oncogenes as to their potential location in the signal-transduction pathways from the outside of the cell to the nucleus (Figure 1 ).
Growth Factors
The archetypal example of an oncogenic growth factor is platelet-derived growth factor (PDGF), the B chain of which is a homolog of the protein encoded by the v-sis gene of the simian sarcoma virus (1-4, 21, 22 Although each of these kinases is distinct with respect to sequence and substrate specificity, members of the arc family share highly conserved noncatalytic sequences known as arc homologr regions 2 and 3 (SH2 and SH3) (44) (45) (46) (47) . SH2 domains have been demonstrated to bind to phosphorylated tyrosine residues, thus providing a mechanism for the formation of stable complexes between the src kinases and other signaling molecules, including receptors. The SH2 motif is found in many of the cytoplasmic signaling molecules, kinases and others, apparently for a similar purpose. The function of the SH3 domain is less clearly defined, although recent evidence points to a role in the association of specific proteins with the cytoskeleton and has been linked to association with small G-proteins (45) (46) (47) .
Src was first identified as a 60-kDa product of the The serine/threonine kinase c-mos has been identified as a component of cytostatic factor, which is involved in the regulation of the cell cycle, in particular the stimulation and arrest of M phase (6, 7, 30, 60, 61). An increase in mos expression induces the activation of the maturation-promoting factor, composed of cyclin B and cdc2 kinase. Selective phosphorylation and dephoaphorylation of maturation-promoting factor is required for the onset of Mphase, and cdc2 kinase has been demonstrated to be a substrate for mos (60, 61). V-mos was initially isolated as a product of the Moloney murine sarcoma virus; mutations of c-mos in human tumors have not yet been observed. Overexpression of c-mos in NIH3T3 cells is sufficient to cause transformation, so it is likely that mos induces its oncogenic effects by overexpression (60, 61) .
Although mutations in the important second messenger protein kinase C (PKC) have not been identified in vivo, it is the target for activation by the phorbol ester tumor promoters. These tumor promoters activate PKC in a fashion similar to that of its physiological activator, diacylglycerol, which is generated in response to receptor-induced turnover of membrane phospholipids (62, 63 76) . GAP also contains a SH2 domain, which may provide a link between ras, tyrosine kinases, and their substrates (17, 44, 45) . Transforming ras proteins often contain point mutations that inactivate their intrinsic GTPase activity, such that ras is present in the constitutively active GTP-bound form (73, 77).
Nuclear Proteins
The end point of the growth factor-mediated signal cascade ultimately lies in the nucleus, where mitogenic signals activate the transcription of genes whose prod- 
Anti-Apoptosis
Genes: Bc12
In an alternative mechanism that may contribute to oncogenesis, 
Tumor-Suppressor
Genes
Oncogenes have been extensively studied and characterized for years, but only within the past decade have the genes responsible for the negative growth regulation of cells, or tumor-suppressor genes, been identified (13-15,19) .
Because they act in opposition to oncogenes, tumor-suppressor genes have also been referred to as anti-oncogenes.
Because both alleles need to be lost to lead to aberrant cell proliferation, they also are frequently called recessive oncogenes.
Tumor-suppressor genes have been primarily
identified by their loss of function, resulting in oncogenesis; therefore, their characterization has been somewhat more difficult than that of the oncogenes, whose gene products are often overexpressed. The exception is p53, which was first characterized as an oncogene (13-15) .
Like the oncogenes, tumor-suppressor genes have been found to act in both the cytoplasm and the nucleus. Two of the best-characterized members of the tumor-suppressor genes discussed herein, p53 and the retinoblastoma gene (RB), are both examples of nuclear anti-oncogenes.
In contrast to the products of oncogenes, which appear to primarily function to induce entry from the G0 phase of the cell cycle into G1, followed by progression through G1 into S phase, the products of p53 and RB appear to function at a "checkpoint" located in late G1. A similar checkpoint with specific mediators is also present at the The mechanism by which the tumor-suppressor genes detect aberrant DNA structure and prevent cell-cycle progression is as yet unknown.
The p53 gene was first identified by its protein, which associates with the SV4O T antigen in virus-infected cells (13-15, 87) . The half-life of the p53 protein in transformed cell lines was observed to be much greater than that found in untransformed cells, leading researchers to believe that they had discovered a new oncogene. Not until investigators realized that the p53 gene used in transfections was, in fact, a mutant form of p53 was the actual function of the wild-type p53 protein elucidated. Wild-type p53 reduced the transforming potential of other oncogenes.
The transforming ability originally attributed to p53 was probably due, at least in part, to the inactivation of the wild-type p53 through interaction or dimerization with the mutant p53 protein. has been demonstrated to bind to specific DNA sequences both in vivo and in vitro and, in fact, has been shown to activate transcription of reporter genes from plasmids that encode upstream p53-binding sites. It appears, then, that p53 activates the transcription of growth-inhibitory genes rather than inhibiting the transcription of growth-promoting genes. Commonly found mutations in p53 destroy the ability of the protein to bind to p53-specific sequences and lose their ability to activate reporter genes (87). p53 is believed to act as a tetramer, and mutations affecting its oligomerization have also been identified.
Mutations of
p53 are the most common defect detected in human cancers. Mutations affecting the activity
RB
The product of the RB gene was first identified through investigation of the familial form of this disease Knudson's hypothesis was confirmed when RB was cloned and localized to chromosome 13 (94) . RB encodes a l1O-kDa nuclear phosphoprotein, which localizes in the nucleus and associates with DNA. Expression of the RB protein has been observed in a wide variety of tissues; however, it is inactivated in only a limited number of tumors.
Similar to p53, wild-type RB seems to play a role in regulating progression through the G1 checkpoint of the cell cycle. RB exists in "hyper-" and "hypo-" phosphory- How RB accomplishes this has yet to be determined.
The association of RB with known transcription factors has been observed, as has its association with DNA. RB 
